I think this is tied to preclinical data, especially if they’re referring to the “mechanism behind the survival outcomes.”

Synergy with Checkpoint Inhibitors?

We had two pre-clinical trials taking place. Saving some of this for the full ESMO presentation?

“We are eager to share additional insights into the apparent mechanism behind the survival outcomes and will do so once appropriate and in compliance with pre-conference publication and announcement allowances.“